With the aim of contributing to people’s health, Toyo Shinyaku Sha, KYORIN Pharmaceutical’s predecessor company, was established in 1923 and began manufacturing and selling injection-type medicines. During the 1960s, we built a structure for the research and development of new drugs. Since then, we have continued to contribute to people’s health through the research and development, manufacture, and sales of new medicines.
Going forward, we will strive to create high value new drugs that meet medical needs and to enhance corporate value, while continuing to grow as a company that makes a wide ranging contribution to people’s health.
- The purple border isCompany history
- The orange border isProduct history
1923年～
1923
Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
1931
Kyorin Chemical Laboratory was established.
1940
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
1947
The Okaya Plant was started.
1950年～
1957
The medical journal bulletin “Doctor Salon” was started.
1961
Behyd, a diuretic and antihypertensive agent, was launched.
1962
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
1965
The Head Office was completed in Kanda Surugadai.
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
1967
The Nogi Plant was opened.
1971
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
1974
Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.
1977
Central Research Laboratories were opened.
1980年～
1980
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).
1981
Mucodyne, a mucoregulant, was launched.
1984
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
1989
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
1992
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.
1993
Megalocin (FLRX), a long-acting new quinolone agent, was launched.
1995
The Noshiro Plant was opened.
1996
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
The Research Center (now the WATARASE Research Center) was founded.
Pentasa, a treatment for ulcerative colitis and Crohn’s disease, was launched.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
1998
Milton, an effervescent disinfectant business, was acquired from P&G.
1999
Listed on the Tokyo Stock Exchange, Second Section.
2000
Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).
2000年～
2001
A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.
Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
2002
A subsidiary company, Kyorin Europe GmbH (Germany), was established.
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
2004
ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.
2005
The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.
2006
The Nogi Plant was closed.
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
2007
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
2008
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
2010
KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc.
2010年～
2012
Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.
RUBYSTA, a multi-purpose disinfectant cleaner, was launched.
2013
Head office moved to Ochanomizu sola city in Kanda Surugadai.
Flutiform, a combination drug for asthma treatment, was launched.
2015
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center (the former Central Research Laboratories) and the R&D Center (the former Research Center).
Eklira Genuair, a treatment for COPD, was launched.
FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)
2016
The Okaya Plant was closed
Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched売
2017
KYORIN Rimedio Co., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.
2018
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.
Beova Tablets 50mg a treatment of OAB drug was launched.
2019
GeneSoC®, a microchannel-based genetic measurement device, was launched.
2020
KYORIN Pharmaceutical Group Facilities Co., Ltd. and KYORIN Medical Supply Co., Ltd. merge.
Lasvic Tablets 75mg an oral quinolone antibacterial agent was launched.
2020年～
2021
Lasvic Intravenous Drip Infusion Kit 150mg an injectable new quinolone antibacterial agent was launched.
Zymso Intravesical Solution 50%, an interstitial cystitis treatmet was launched.
GeneSoC® mini was launched.
2022
Lyfnua® Tablets 45mg Selective P2X3 receptor antagonist/Refractory chronic cough was launched.
ActivX Biosciences, Inc. was dissolved.
2023
KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical Co., Ltd. through absorption type merger of KYORIN Pharmaceutical Co., Ltd.
2024
The Takaoka Plant was opened.
